Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Alkermes's interest expense for the
three
months ended in Mar. 2026 was $ -21 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-33 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Alkermes's Operating Income for the
three
months ended in Mar. 2026 was $ -48 Mil. Alkermes's Interest Expense for the
three
months ended in Mar. 2026 was $ -21 Mil.
Alkermes did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Alkermes (NAS:ALKS) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Alkermes's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
Alkermes did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Alkermes Interest Expense Historical Data
* Premium members only.
The historical data trend for Alkermes's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkermes (ALKS) has a Interest Expense of $-33 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Alkermes and its competitors.
Is Alkermes' Interest Expense too high?
Alkermes' current Interest Expense is $-33 Mil. Overall, Alkermes has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Interest Expense compare to HIMS and LNTH?
Alkermes' Interest Expense of $-33 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Alkermes and its competitors. Alkermes's current Interest Expense is $-33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.52, compared to a current price of $51.74 — trading 64.1% above its estimated fair value. The current Interest Expense is $-33 Mil. Alkermes' overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Alkermes (ALKS), the current Interest Expense is $-33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkermes (ALKS) Overvalued in 2026?
Based on GuruFocus' analysis, Alkermes stock appears to be overvalued.
The current stock price of $51.74 is trading 64.1% above its estimated GF Value™ of $31.52.
GuruFocus considers Alkermes to be Significantly Overvalued.
Key valuation signals for ALKS:
Interest Expense: $-33 Mil
GF Value™: $31.52 vs. price of $51.74 (64.1% above fair value)
No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
69GF Score
Get the complete analysis for ALKS
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALKS has been successfully added to your 
